Kaiser Health News/NPR: Are Golden Tickets That Speed Drugs Through FDA Worthwhile?
“…Members of Congress, the pharmaceutical industry, and rare disease advocates have passionately supported [priority review] vouchers as a way to spur development of drugs for rare and neglected diseases. But skeptics, including FDA officials and some academics, have questioned whether the program is paying off…” (Tribble, 9/29).